Can we prevent, reduce or reverse intestinal fibrosis in IBD?
about
Medical Therapy of Fibrostenotic Crohn's DiseaseOrganoid-based epithelial to mesenchymal transition (OEMT) model: from an intestinal fibrosis perspective.The possible prognostic role of histone deacetylase and transforming growth factor β/Smad signaling in high grade gliomas treated by radio-chemotherapy: a preliminary immunohistochemical studyAnti-fibrogenic effect of PPAR-γ agonists in human intestinal myofibroblasts.Medical therapy of stricturing Crohn's disease: what the gut can learn from other organs - a systematic review.Telocytes are reduced during fibrotic remodelling of the colonic wall in ulcerative colitisTriptolide ameliorates colonic fibrosis in an experimental rat modelRole of glycogen synthase kinase-3β and PPAR-γ on epithelial-to-mesenchymal transition in DSS-induced colorectal fibrosis.Novel PPARγ Modulator GED-0507-34 Levo Ameliorates Inflammation-driven Intestinal Fibrosis.Isolation of CD 90+ Fibroblast/Myofibroblasts from Human Frozen Gastrointestinal Specimens.PET/MR Versus PET/CT Imaging: Impact on the Clinical Management of Small-Bowel Crohn's Disease.Curcumin Suppresses Intestinal Fibrosis by Inhibition of PPARγ-Mediated Epithelial-Mesenchymal TransitionSignificant contribution of TRPC6 channel-mediated Ca2+ influx to the pathogenesis of Crohn's disease fibrotic stenosis.Cellular and Molecular Mediators of Intestinal Fibrosis.Collagenous sprue: a coeliac disease look-alike with different treatment strategy.Stromal and immune cells in gut fibrosis: the myofibroblast and the scarface.Factors Promoting Development of Fibrosis in Crohn's Disease.Precision-cut rat, mouse, and human intestinal slices as novel models for the early-onset of intestinal fibrosisActivation of Myofibroblast TRPA1 by Steroids and Pirfenidone Ameliorates Fibrosis in Experimental Crohn's Disease.Daikenchuto (Da-Jian-Zhong-Tang) ameliorates intestinal fibrosis by activating myofibroblast transient receptor potential ankyrin 1 channel
P2860
Q26777724-7FDCC583-E69D-437C-8DAA-B9141E5419F7Q30853689-AA5A9B0D-DBF8-4A1E-94FA-C7ED62480C02Q33712267-3E1FC7DB-82D2-4B70-A500-F699B35C9AD2Q33776469-D8D07F27-230B-45F0-9817-9BEA24509BD7Q34504710-D46D80BC-67C5-4F9D-877D-2B8B7893ABD4Q34885334-A8C927BF-2445-4208-ABEC-02BE07B35ACAQ35727035-2FDCAA05-682D-4BD4-9626-1483FE8EED00Q36282521-06F530C1-200E-43B1-A2AE-BC0BA4836C95Q36479876-ACD137E7-AD6F-4C6E-9809-44418AB7121DQ36660621-BC8D7A93-7F3F-4E4B-AE8C-DD58F502BE19Q37118454-D0370767-8318-4A95-B2FF-B43335B6EF63Q37624991-F4953392-BF1D-42C6-BC90-8C93E41FC48EQ37660726-023AADD9-C239-4555-81FA-131724A2F7F0Q38259227-FFA5948D-2298-4FF7-AE6C-DE26402495AEQ38613707-C8D2B6D4-A4E9-4314-849C-CA65A4A7EAC9Q39401444-707D71E0-44F1-4FB7-B0F5-E84A1E89ECB9Q39453646-8428F794-9519-4C23-BF94-051D1AE236ADQ40487416-1A717ED0-4EC0-46A4-9295-6F892F42F8E0Q52430882-E8083ABB-D978-4EFE-90F6-837E97B854A3Q58707775-05BD3851-75EA-4501-BDF5-8C80A7D5BBCD
P2860
Can we prevent, reduce or reverse intestinal fibrosis in IBD?
description
2013 nî lūn-bûn
@nan
2013 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Can we prevent, reduce or reverse intestinal fibrosis in IBD?
@ast
Can we prevent, reduce or reverse intestinal fibrosis in IBD?
@en
Can we prevent, reduce or reverse intestinal fibrosis in IBD?
@nl
type
label
Can we prevent, reduce or reverse intestinal fibrosis in IBD?
@ast
Can we prevent, reduce or reverse intestinal fibrosis in IBD?
@en
Can we prevent, reduce or reverse intestinal fibrosis in IBD?
@nl
prefLabel
Can we prevent, reduce or reverse intestinal fibrosis in IBD?
@ast
Can we prevent, reduce or reverse intestinal fibrosis in IBD?
@en
Can we prevent, reduce or reverse intestinal fibrosis in IBD?
@nl
P2093
P1476
Can we prevent, reduce or reverse intestinal fibrosis in IBD?
@en
P2093
P304
P407
P577
2013-05-01T00:00:00Z